Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Essential Tremor Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Essential Tremor Overview | 7 | 1 |
| Essential Tremor Therapeutics under Development by Companies | 8 | 1 |
| Essential Tremor Pipeline Products Glance | 9 | 2 |
| Clinical Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Essential Tremor Products under Development by Companies | 11 | 1 |
| Essential Tremor Companies Involved in Therapeutics Development | 12 | 3 |
| Merz GmbH &Co. KGaA | 12 | 1 |
| Neurocrine Biosciences, Inc. | 13 | 1 |
| Sage Therapeutics, Inc. | 14 | 1 |
| Essential Tremor Therapeutics Assessment | 15 | 9 |
| Assessment by Monotherapy Products | 15 | 1 |
| Assessment by Target | 16 | 2 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Drug Profiles | 24 | 9 |
| incobotulinumtoxin A - Drug Profile | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 3 |
| NBI-640756 - Drug Profile | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| SAGE-217 - Drug Profile | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| sepranolone - Drug Profile | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 3 |
| Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| Essential Tremor Recent Pipeline Updates | 33 | 8 |
| Essential Tremor - Dormant Projects | 41 | 1 |
| Essential Tremor Discontinued Products | 42 | 1 |
| Essential Tremor Product Development Milestones | 43 | 5 |
| Featured News &Press Releases | 43 | 1 |
| Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting | 43 | 1 |
| Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline | 44 | 1 |
| Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor | 45 | 2 |
| Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor | 47 | 1 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |